- Home
- ALLR vs BIVI Comparison
ALLR vs BIVI Comparison
Compare ALLR & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- BIVI
- Stock Information
- Founded
- ALLR 2004
- BIVI 2013
- Country
- ALLR United States
- BIVI United States
- Employees
- ALLR N/A
- BIVI N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- BIVI Health Care
- Exchange
- ALLR Nasdaq
- BIVI Nasdaq
- Market Cap
- ALLR 15.8M
- BIVI 15.0M
- IPO Year
- ALLR N/A
- BIVI N/A
- Fundamental
- Price
- ALLR $1.01
- BIVI $7.19
- Analyst Decision
- ALLR
- BIVI
- Analyst Count
- ALLR 0
- BIVI 0
- Target Price
- ALLR N/A
- BIVI N/A
- AVG Volume (30 Days)
- ALLR 417.1K
- BIVI 42.5K
- Earning Date
- ALLR 08-04-2025
- BIVI 05-12-2025
- Dividend Yield
- ALLR N/A
- BIVI N/A
- EPS Growth
- ALLR N/A
- BIVI N/A
- EPS
- ALLR N/A
- BIVI N/A
- Revenue
- ALLR N/A
- BIVI N/A
- Revenue This Year
- ALLR N/A
- BIVI N/A
- Revenue Next Year
- ALLR N/A
- BIVI N/A
- P/E Ratio
- ALLR N/A
- BIVI N/A
- Revenue Growth
- ALLR N/A
- BIVI N/A
- 52 Week Low
- ALLR $0.61
- BIVI $6.20
- 52 Week High
- ALLR $7.45
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- ALLR 53.22
- BIVI 31.41
- Support Level
- ALLR $0.95
- BIVI $6.78
- Resistance Level
- ALLR $1.08
- BIVI $10.30
- Average True Range (ATR)
- ALLR 0.07
- BIVI 0.86
- MACD
- ALLR 0.01
- BIVI -0.29
- Stochastic Oscillator
- ALLR 59.39
- BIVI 19.17
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.